Double maintains 3 strategies that include ACAD - ACADIA Pharmaceuticals, Inc.
Current Value
$18.371 Year Return
Current Value
$18.371 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
INSP | -11.71% | $4.41B | -5.87% | 0.00% |
CBOE | -9.22% | $22.95B | +20.67% | 1.12% |
FTNT | -8.63% | $78.50B | +67.47% | 0.00% |
ZCMD | -8.33% | $32.45M | -11.38% | 0.00% |
CODI | -7.51% | $580.07M | -65.16% | 12.97% |
LITB | -7.05% | $21.28M | -72.45% | 0.00% |
STG | -6.48% | $27.05M | -37.35% | 0.00% |
CARV | -5.51% | $7.41M | -22.87% | 0.00% |
FMTO | -4.94% | $45.74M | -99.96% | 0.00% |
VSTA | -4.47% | $326.82M | +11.64% | 0.00% |
NEUE | -4.11% | $62.05M | +13.56% | 0.00% |
TAK | -4.10% | $44.06B | +5.18% | 2.33% |
INGN | -2.86% | $154.60M | -35.75% | 0.00% |
CME | -2.65% | $98.74B | +28.80% | 3.84% |
HEES | -2.41% | $3.52B | +99.54% | 1.15% |
COR | -2.39% | $55.43B | +28.90% | 0.56% |
SMWB | -1.76% | $609.62M | -5.76% | 0.00% |
VHC | -1.57% | $34.69M | +74.89% | 0.00% |
SEG | -1.18% | $239.93M | -26.61% | 0.00% |
YOU | -0.93% | $2.29B | +42.87% | 1.82% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SGC | 50.58% | $161.10M | -49.50% | 5.58% |
EBS | 49.55% | $297.99M | +4.17% | 0.00% |
SPCE | 46.37% | $133.97M | -83.74% | 0.00% |
TREX | 43.70% | $6.44B | -32.28% | 0.00% |
EHAB | 43.40% | $544.86M | +28.86% | 0.00% |
LYFT | 43.09% | $6.83B | -4.25% | 0.00% |
CRSP | 42.98% | $3.14B | -34.78% | 0.00% |
VVV | 42.67% | $4.35B | -18.99% | 0.00% |
CRL | 42.02% | $6.82B | -38.20% | 0.00% |
VYX | 41.90% | $1.50B | -18.43% | 0.00% |
QTWO | 41.72% | $5.63B | +47.41% | 0.00% |
TCPC | 41.42% | - | - | 16.45% |
EYE | 40.94% | $1.47B | +16.21% | 0.00% |
GFF | 40.71% | $3.42B | +7.00% | 0.90% |
PRVA | 40.45% | $3.04B | +46.47% | 0.00% |
TECH | 40.38% | $7.56B | -41.77% | 0.49% |
NTLA | 40.27% | $836.43M | -69.14% | 0.00% |
IOSP | 40.21% | $2.20B | -32.27% | 1.77% |
SCS | 40.15% | $1.21B | -22.68% | 3.80% |
RGNX | 40.01% | $433.39M | -46.03% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -28.23% | $361.41M | 1.43% |
TAIL | -27.00% | $140.49M | 0.59% |
VIXY | -26.49% | $109.64M | 0.85% |
ULST | -19.70% | $637.77M | 0.2% |
FTSD | -18.48% | $212.46M | 0.25% |
IVOL | -14.85% | $353.94M | 1.02% |
FXE | -9.30% | $525.40M | 0.4% |
TFLO | -8.73% | $7.06B | 0.15% |
XHLF | -8.29% | $1.46B | 0.03% |
LDUR | -7.76% | $849.09M | 0.5% |
UDN | -5.60% | $137.74M | 0.78% |
XONE | -5.45% | $603.24M | 0.03% |
SCHO | -5.18% | $10.87B | 0.03% |
SPTS | -4.86% | $5.76B | 0.03% |
FXY | -4.22% | $838.61M | 0.4% |
SPSK | -4.00% | $307.27M | 0.5% |
VGSH | -3.76% | $22.38B | 0.03% |
CLIP | -3.23% | $1.50B | 0.07% |
UNG | -3.13% | $371.83M | 1.06% |
UTWO | -2.47% | $387.71M | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BILS | -0.21% | $3.96B | 0.1356% |
AGZD | 0.24% | $127.42M | 0.23% |
IBND | 0.31% | $291.26M | 0.5% |
WEAT | -0.42% | $115.83M | 0.28% |
FXC | -0.46% | $87.40M | 0.4% |
KCCA | 0.91% | $97.18M | 0.87% |
IBTH | -1.00% | $1.53B | 0.07% |
IBMN | 1.11% | $446.12M | 0.18% |
TPMN | -1.11% | $31.54M | 0.65% |
NEAR | 1.17% | $3.26B | 0.25% |
GLDM | 1.20% | $14.42B | 0.1% |
YEAR | 1.26% | $1.40B | 0.25% |
SHY | 1.45% | $24.03B | 0.15% |
SGOL | 1.49% | $5.06B | 0.17% |
IAU | 1.59% | $45.68B | 0.25% |
IEI | 1.62% | $16.09B | 0.15% |
SHYM | -1.69% | $322.93M | 0.35% |
AAAU | 1.77% | $1.47B | 0.18% |
IBTG | 1.78% | $1.88B | 0.07% |
FTSM | 1.80% | $6.54B | 0.45% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
VSA | -0.02% | $7.04M | -49.24% | 0.00% |
PHYS.U | 0.16% | - | - | 0.00% |
HDB | -0.23% | $187.13B | +30.85% | 0.95% |
PAYO | -0.26% | $2.57B | +21.16% | 0.00% |
MO | -0.30% | $97.80B | +26.35% | 6.94% |
LTM | 0.30% | $11.01B | -96.75% | 2.75% |
GLOB | -0.47% | $5.85B | -25.26% | 0.00% |
FUBO | -0.47% | $1.01B | +121.80% | 0.00% |
AIFU | 0.57% | $9.85M | -95.03% | 0.00% |
EXEL | 0.58% | $12.62B | +117.90% | 0.00% |
PM | -0.61% | $263.27B | +68.03% | 3.17% |
ATUS | 0.62% | $1.32B | +34.76% | 0.00% |
SRRK | 0.64% | $2.92B | +115.29% | 0.00% |
LRN | -0.86% | $6.69B | +118.03% | 0.00% |
K | -0.87% | $28.49B | +32.17% | 2.77% |
YOU | -0.93% | $2.29B | +42.87% | 1.82% |
ASPS | 1.09% | $69.98M | -57.72% | 0.00% |
ED | 1.10% | $36.75B | +5.26% | 3.28% |
SEG | -1.18% | $239.93M | -26.61% | 0.00% |
DG | 1.44% | $20.45B | -36.56% | 2.55% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 50.51% | $4.85B | 0.35% |
PBE | 49.53% | $214.12M | 0.58% |
IBB | 49.29% | $5.22B | 0.45% |
GNOM | 47.69% | $40.65M | 0.5% |
FBT | 47.14% | $994.71M | 0.56% |
XPH | 46.86% | $136.58M | 0.35% |
ARKG | 45.73% | $944.78M | 0.75% |
IWC | 44.85% | $766.88M | 0.6% |
IWO | 44.82% | $11.36B | 0.24% |
BBH | 44.56% | $327.42M | 0.35% |
CPRJ | 44.53% | $48.43M | 0.69% |
KJUL | 44.43% | $113.35M | 0.79% |
FXH | 44.23% | $891.82M | 0.62% |
RSPH | 43.84% | $754.08M | 0.4% |
VTWO | 43.66% | $12.07B | 0.07% |
IWM | 43.51% | $63.95B | 0.19% |
GSSC | 43.42% | $538.65M | 0.2% |
PINK | 43.34% | $131.52M | 0.5% |
SCHA | 43.25% | $16.91B | 0.04% |
VHT | 42.99% | $14.92B | 0.09% |
Yahoo
Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $19 from $17 and keeps a Perform rating on the shares. The firm sees the Delaware court’s verdict in favor of Acadia as consistent with its expectations for Nuplazid intellectual property protection while removing a perceived overhang on the shares. The court specifically concluded that Acadia demonstrated by preponderance of evidence that Aurobindo infringes patent claims, the analyst tells investors in a research no
Yahoo
BMO Capital analyst Evan Seigerman notes that a U.S. district court issued a ruling in favor of Acadia Pharmaceuticals (ACAD) in their Nuplazid patent infringement lawsuit with Aurobindo, confirming today that Aurobindo infringed on claims 4 and 5 of Acadia’s 11,452,721 U.S. formulation patent. Today’s announcement likely extends the lifespan of pimavanserin and could extend the company’s patent protection from 2030 to 2038, removing a “key overhang,” says the analyst, who reiterates an Outperfo
SeekingAlpha
Acadia Pharmaceuticals strengthens Nuplazid's IP, anticipates stabilization in commercial performance, and eyes future pipeline value. Read more on how ACAD stock is a Buy.
Yahoo
SAN DIEGO, May 16, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID® (pimavanserin), Acadia’s drug for the treatment of Parkinson’s Disease Psychosis. In today’s order, the Court ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated New
Finnhub
ACADIA Pharmaceuticals Inc: * DELAWARE DISTRICT COURT RULES IN FAVOR OF ACADIA INNUPLAZID® FORMULATION PATENT LITIGATION * ACADIA PHARMACEUTICALS INC - COURT UPHOLDS...
SeekingAlpha
Discover ACADIA Pharmaceuticals' strong Q1 results, robust balance sheet and promising drug pipeline.